AGC will manufacture Matrix-M, the adjuvant component of the vaccine candidate that helps enhance the immune response and stimulate high levels of neutralizing antibodies. The vaccine candidate is a prefusion protein made using Novavax's proprietary nanoparticle technology.
AGC plans to optimize process development for rapid scale-up of Matrix-M to increase Novavax's capacity to deliver doses of the vaccine this year. Phase I clinical trial results for NVX-CoV2373 are expected in July.
Copyright © 2020 scienceboard.net